Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | PARG | Q86W56 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4810265 | 0.86 | CYP3A4 (0.62) | CYP3A4PKMHPGDALDH1A1TP53 | |
| Acetic Acid SCHEMBL4803470 | 0.83 | CYP3A4 (0.72) | CYP3A4PKMHPGDALDH1A1KDM4E | |
| SCHEMBL4812436 | 0.80 | PKM (0.60) | PKMHPGDPARGRXFP1ALDH1A1 | |
| SCHEMBL9748739 | 0.75 | CYP3A4 (0.68) | CYP3A4HPGDPARGRXFP1ALDH1A1 | |
| Acetic Acid SCHEMBL4812178 | 0.74 | CYP3A4 (0.71) | CYP3A4PKMHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL4809767 | 0.74 | CYP3A4 (0.66) | CYP3A4PKMHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL4802821 | 0.68 | PKM (0.53) | PKMHPGDRXFP1ALDH1A1SMN1; SMN2 | |
| Amisometradine SCHEMBL309300 | 0.67 | ALDH1A1 (0.57) | CYP3A4HPGDALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1278968 | 0.65 | ALDH1A1 (0.61) | CYP3A4HPGDALDH1A1KDM4ETP53 | |
| SCHEMBL1146000 | 0.65 | SMN1; SMN2 (0.59) | CYP3A4HPGDALDH1A1KDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361661-B2 | 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors | NOVARTIS AG (CH) | 2008-04-22 | — | — | US | disclosed |
| US-20060173181-A1 | 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors | BHALAY GURDIP | 2006-08-03 | — | — | US | disclosed |
| US-20060106214-A1 | 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors | NOVARTIS AG (CH) | 2006-05-18 | — | — | US | disclosed |
| US-7019136-B2 | 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors | NOVARTIS, AG (CH) | 2006-03-28 | — | — | US | disclosed |
| US-6919337-B2 | 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors | NOVARTIS, AG (CH) | 2005-07-19 | — | — | US | disclosed |
| US-20050054660-A1 | 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors | BHALAY GURDIP (GB) | 2005-03-10 | — | — | US | disclosed |
| CN-1176922-C | 8-quinolinxanthine and 8-isoquinolinxanthine derivs. as PDE 5 inhibitors | ��˹��ŵ�� | 2004-11-24 | — | — | CN | disclosed |
| US-20040038996-A1 | 8-Quinolinxanthine and 8-isoquinolinxant hine derivatives as PDE 5 inhibitors | NOVARTIS AG (CH) | 2004-02-26 | — | — | US | disclosed |
| EP-1268480-B1 | 8-QUINOLINXANTHINE AND 8-ISOQUINOLINXANTHINE DERIVATIVES AS PDE 5 INHIBITORS | NOVARTIS AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| US-20030171384-A1 | 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors | BHALAY GURDIP (GB) | 2003-09-11 | — | — | US | disclosed |
| US-20030114469-A1 | Combinations | COHEN DAVID SAUL (US) | 2003-06-19 | — | — | US | disclosed |
| CN-1420887-A | 8-quinolinxanthine and 8-isoquinolinxanthine derivs. as PDE 5 inhibitors | NOVARTIS AG (CH) | 2003-05-28 | — | — | CN | disclosed |
| EP-1268480-A1 | 8-QUINOLINXANTHINE AND 8-ISOQUINOLINXANTHINE DERIVATIVES AS PDE 5 INHIBITORS | Novartis AG (CH) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001077110-A1 | 8-QUINOLINXANTHINE AND 8-ISOQUINOLINXANTHINE DERIVATIVES AS PDE 5 INHIBITORS | NOVARTIS AG (CH) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114469-A1 | Combinations | GPR119, SLC5A1, HMGCR | CYP3A4 1061/4885PKM 1788/4885HPGD 390/4885 |
| US-20060106214-A1 | 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors | PDE5A, PDE3A, PDE2A | CYP3A4 634/4885PKM 2207/4885HPGD 355/4885 |
| US-20050054660-A1 | 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors | PDE5A, PDE3A, PDE2A | CYP3A4 618/4885PKM 2083/4885HPGD 342/4885 |
| US-20040038996-A1 | 8-Quinolinxanthine and 8-isoquinolinxant hine derivatives as PDE 5 inhibitors | PDE5A, PDE3A, PDE2A | CYP3A4 730/4885PKM 2447/4885HPGD 251/4885 |
| US-20060173181-A1 | 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors | PDE5A, PDE3A, PDE2A | CYP3A4 618/4885PKM 2083/4885HPGD 342/4885 |
| US-20030171384-A1 | 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors | PDE5A, PDE3A, PDE2A | CYP3A4 1064/4885PKM 2266/4885HPGD 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.